143 related articles for article (PubMed ID: 24418743)
21. Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran.
Amirifard N; Sadeghi E
Asian Pac J Cancer Prev; 2016; 17(5):2593-6. PubMed ID: 27268636
[TBL] [Abstract][Full Text] [Related]
22. Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas.
Matsuo K; Fukutomi T; Watanabe T; Hasegawa T; Tsuda H; Akashi-Tanaka S
Breast Cancer; 2002; 9(1):75-81. PubMed ID: 12196726
[TBL] [Abstract][Full Text] [Related]
23. Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI.
Tozaki M; Uno S; Kobayashi T; Aiba K; Yoshida K; Takeyama H; Shioya H; Tabei I; Toriumi Y; Suzuki M; Kawakami M; Fukuda K
Radiat Med; 2004; 22(4):246-53. PubMed ID: 15468945
[TBL] [Abstract][Full Text] [Related]
24. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up.
Jung M; Shin HJ; Rha SY; Jeung HC; Hong S; Moon YW; Kim HS; Oh KJ; Yang WI; Roh JK; Chung HC
Ann Surg Oncol; 2010 Dec; 17(12):3259-68. PubMed ID: 20563656
[TBL] [Abstract][Full Text] [Related]
25. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
26. Perspectives on preoperative staging with breast MRI.
Hollingsworth AB
J Am Coll Surg; 2004 Jul; 199(1):173-4. PubMed ID: 15217651
[No Abstract] [Full Text] [Related]
27. Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study.
Chen J; Yao Q; Li D; Zhang J; Wang T; Yu M; Zhou X; Huan Y; Wang J; Wang L
BMC Cancer; 2013 May; 13():248. PubMed ID: 23693018
[TBL] [Abstract][Full Text] [Related]
28. Incidence of interstitial pneumonitis in breast cancer patients treated with pegylated liposomal doxorubicin.
Meng L; Huang L; Xu Y; Zhang W
Cancer Chemother Pharmacol; 2020 Jan; 85(1):3-7. PubMed ID: 31377831
[TBL] [Abstract][Full Text] [Related]
29. [Differences between clinical response and pathologic response of breast cancer after neoadjuvant chemotherapy].
Zheng S; Zhang BL; Zhang RZ; Yang JL; Zou SM; Xue LY; Luo W; Yuan YL; Lü N
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):734-8. PubMed ID: 21215162
[TBL] [Abstract][Full Text] [Related]
30. [Lymph node metastasis and prognostic analysis of 354 cases of T1 breast cancer].
Lyu Z; Wang J; Kang L; Hu C; He H; Guan M; Li J; Guan Y; Song Y
Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):382-5. PubMed ID: 25030596
[TBL] [Abstract][Full Text] [Related]
31. ASO Author Reflections: Selecting Patients for Elimination of Surgery Trials-Predicting Residual Invasive and In Situ Disease in Patients with HER2-Positive Breast Cancer After Neoadjuvant Systemic Therapy.
Sun SX; Kuerer HM
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):804-805. PubMed ID: 31654165
[No Abstract] [Full Text] [Related]
32. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
[TBL] [Abstract][Full Text] [Related]
33. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Llombart-Cussac A; Cortés J; Paré L; Galván P; Bermejo B; Martínez N; Vidal M; Pernas S; López R; Muñoz M; Nuciforo P; Morales S; Oliveira M; de la Peña L; Peláez A; Prat A
Lancet Oncol; 2017 Apr; 18(4):545-554. PubMed ID: 28238593
[TBL] [Abstract][Full Text] [Related]
34. Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens.
Goldstein LJ; Gurtler J; Del Prete SA; Tjulandin S; Semiglazov VF; Bayever E; Michiels B
Clin Breast Cancer; 2014 Dec; 14(6):396-404. PubMed ID: 25239225
[TBL] [Abstract][Full Text] [Related]
35. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
Kuehn T; Bauerfeind I; Fehm T; Fleige B; Hausschild M; Helms G; Lebeau A; Liedtke C; von Minckwitz G; Nekljudova V; Schmatloch S; Schrenk P; Staebler A; Untch M
Lancet Oncol; 2013 Jun; 14(7):609-18. PubMed ID: 23683750
[TBL] [Abstract][Full Text] [Related]
36. Factors associated with receipt of adjuvant chemotherapy among married women with breast cancer.
Zhang Y; Gao H; Bu Y; Fan X; Jia J
World J Surg Oncol; 2013 Oct; 11():286. PubMed ID: 24175997
[TBL] [Abstract][Full Text] [Related]
37. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
[TBL] [Abstract][Full Text] [Related]
38. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Saloustros E; Malamos N; Kakolyris S; Boukovinas I; Papakotoulas P; Kentepozidis N; Ziras N; Georgoulias V;
Ann Oncol; 2015 Jul; 26(7):1333-40. PubMed ID: 25935793
[TBL] [Abstract][Full Text] [Related]
39. Overuse of Preoperative Staging of Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer.
Srour MK; Lee M; Walcott-Sapp S; Luu M; Chung A; Giuliano AE; Amersi F
Ann Surg Oncol; 2019 Oct; 26(10):3289-3294. PubMed ID: 31342365
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant chemotherapy for elderly patients (> or =70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients.
Brunello A; Basso U; Pogliani C; Jirillo A; Ghiotto C; Koussis H; Lumachi F; Iacobone M; Vamvakas L; Monfardini S
Ann Oncol; 2005 Aug; 16(8):1276-82. PubMed ID: 15919685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
